Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis

From the Division of Arthritis & Rheumatic Diseases, Rheumatology Clinics, Oregon Health & Science University, Portland, Oregon, USA; Health Network, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; Centre for Rheumatic Diseases, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK; PKS Bioanalytics, Novartis Institutes for Biomedical Research, Basel; Immunology and Dermatology, Novartis Pharma AG, Basel, Switzerland; Immunology and Dermatology, Novartis Pharmaceuticals Corp., East Hanover, New Jersey, USA.